drugset / Trial / NCT04208464
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
Phase 2
Completed
15 enrolled
University of Manchester
Clinical Trials Unit, Manchester · collabEli Lilly and Company · collabKarolinska Institutet · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aims to investigate the clinical efficacy of baricitinib in patients with adult idiopathic inflammatory myositis (IIM). Half of the patients enrolled onto the study will receive 24 weeks of baricitinib from the baseline visit with a 12 week follow-up period. The other half of patients will receive 24 weeks of barcitinib treatment after an initial 12-week delay with a 4 week follow up period for safety.
Timeline
- Start
- 2021-10-07
- Primary completion
- 2023-09-25
- Completion
- 2023-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |